Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SLIT-ROBO Rho GTPase-activating protein 3 (SRGAP3) is a protein encoded by the SRGAP3 gene on chromosome 3, primarily expressed in the central nervous system, especially in regions critical for higher cognitive functions such as the hippocampus and cortex[1][4]. It acts as a GTPase-activating protein (GAP) for RAC1, and potentially CDC42, thereby negatively regulating specific Rho family small GTPases involved in actin cytoskeleton remodeling and neuronal plasticity[1][2][6]. SRGAP3 is an intracellular effector in the Slit-Robo signaling pathway that governs neuronal migration and axonal branching, and its disruption has been linked to intellectual disability and abnormal neuronal development[1][2][3]. SRGAP3 is also referred to by alternative names such as MEGAP (Mental disorder-associated GAP) and ARHGAP14, and shares structural and functional similarities with other RhoGAP family proteins[1]. The protein contains key functional domains: an SH3 domain, a FES/CIP4 (FCH) domain, and the RhoGAP domain[1]. Loss or mutation of SRGAP3 can cause severe neurodevelopmental phenotypes due to impaired neuronal migration and synaptic assembly[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SLIT-ROBO Rho GTPase-activating protein 3 (SRGAP3).